Last reviewed · How we verify
CLA (Clarithro+Lanso+Amoxi)
CLA (Clarithro+Lanso+Amoxi) is a Antibiotic combination with proton pump inhibitor Small molecule drug developed by Asofarma de México S.A de C.V.. It is currently in Phase 3 development for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis. Also known as: Pylopac®, Medix, Mexico.
CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole).
CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole). Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | CLA (Clarithro+Lanso+Amoxi) |
|---|---|
| Also known as | Pylopac®, Medix, Mexico |
| Sponsor | Asofarma de México S.A de C.V. |
| Drug class | Antibiotic combination with proton pump inhibitor |
| Target | H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Clarithromycin and amoxicillin are bactericidal antibiotics that inhibit H. pylori protein synthesis and cell wall integrity, respectively. Lansoprazole, a proton pump inhibitor, reduces gastric acid to create an optimal pH environment for antibiotic efficacy and promote ulcer healing. This triple combination is a standard regimen for H. pylori eradication.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Taste disturbance
- Headache
- Allergic reactions (amoxicillin)
Key clinical trials
- Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLA (Clarithro+Lanso+Amoxi) CI brief — competitive landscape report
- CLA (Clarithro+Lanso+Amoxi) updates RSS · CI watch RSS
- Asofarma de México S.A de C.V. portfolio CI
Frequently asked questions about CLA (Clarithro+Lanso+Amoxi)
What is CLA (Clarithro+Lanso+Amoxi)?
How does CLA (Clarithro+Lanso+Amoxi) work?
What is CLA (Clarithro+Lanso+Amoxi) used for?
Who makes CLA (Clarithro+Lanso+Amoxi)?
Is CLA (Clarithro+Lanso+Amoxi) also known as anything else?
What drug class is CLA (Clarithro+Lanso+Amoxi) in?
What development phase is CLA (Clarithro+Lanso+Amoxi) in?
What are the side effects of CLA (Clarithro+Lanso+Amoxi)?
What does CLA (Clarithro+Lanso+Amoxi) target?
Related
- Drug class: All Antibiotic combination with proton pump inhibitor drugs
- Target: All drugs targeting H. pylori bacterial ribosomes (clarithromycin); H. pylori cell wall (amoxicillin); gastric H+/K+-ATPase (lansoprazole)
- Manufacturer: Asofarma de México S.A de C.V. — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Infectious Disease
- Indication: Drugs for Helicobacter pylori infection eradication in peptic ulcer disease
- Indication: Drugs for H. pylori-associated gastritis
- Also known as: Pylopac®, Medix, Mexico
- Compare: CLA (Clarithro+Lanso+Amoxi) vs similar drugs
- Pricing: CLA (Clarithro+Lanso+Amoxi) cost, discount & access